BIO Professional Development
Through a curated network of education alliance partners, BIO offers industry professionals executive training and development resources for accelerating career growth
06/19/2026 - 06/21/2026 | 8:30 AM - 5:45 PM EDT
Advanced Business Development
Advanced Business Development (ABD) is a long-running course focusing on all key aspects of transactions in the biopharma industry. This course is ideal for professionals ranging from those with limited experience (2–3 years) looking to advance their skills; and highly experienced dealmakers or executives looking to hone their skills and network with other dealmakers.
Advanced Business Development incorporates lectures from experienced dealmakers, review of example models, dissection of actual deals, interaction with other participants, and live Q&A. Also, the course includes a mock negotiation scenario when each participant is a member of a deal team assigned to negotiate a transaction involving a drug in development with another team using an actual valuation and deal structuring model.
This three-day course will be held in person, June 19--21, 2026, in San Diego, Calif. Registration will open in early February 2026.
Have additional questions about the BIO Professional Development Program? Please email: courseshelp@bio.org
Instructors (click photos to view bios)
Takeaways
- Business development practices
- Trends in BD transactions
- Valuation, analytics, and models
- Deal structuring
- Negotiation
- Intellectual property
- Legal terms, term sheets, and agreements
- Due diligence
- Live, interactive case study work
Certificate Requirements
- Attend the entire in-person course
- Complete course evaluation within two weeks of the course end date
A digital strategy can no longer lie within a siloed digital or innovation team. It’s critical to integrate digital across the enterprise to maintain a competitive edge.
A good regulatory strategy is essential to a good business strategy.
Gain a systematic approach to producing a valuation that can be used in investment rounds, mergers/acquisitions, licensing deals or strategic development decisions in the pharma-biotech world...